We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Collaboration on Reagents for Biodectection

By Biotechdaily staff writers
Posted on 05 Nov 2002
A collaboration to develop and sell reagents to detect biothreat agents has been announced by Cepheid (Sunnyvale, CA, USA) and Applied Biosystems Group (Foster City, CA, USA).

The reagents will be used with Cepheid's GeneXpert system and cartridges and be directed to the biologic detection system (BDS) currently being developed for potential deployment within United States Postal Service (USPS) mail sorting facilities by a consortium led by Northrop Grumman Corporation, which includes Cepheid. Additional terms of the agreement were not disclosed.

The combination of Applied Biosystems' reagent development capability and extensive experience in the field of real-time DNA testing will strongly complement Cepheid's expertise in developing real-time genetic testing systems,” said Tom Gutshall, chairman of Cepheid. "Cepheid's unique GeneXpert system and test cartridges enable the benefits of genetic testing to be taken to the point of need, such as in a USPS facility, advancing our nation's ability to rapidly and precisely identify the presence of biothreat agents.”




Related Links:
Cepheid
Applied Biosystems

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Urinalysis Solution
UN-9000
New
All-in-One Molecular System
AIO M160

Latest BioResearch News

Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
05 Nov 2002  |   BioResearch

Genetic Cause Identified for Severe Infant Epilepsy
05 Nov 2002  |   BioResearch

Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
05 Nov 2002  |   BioResearch



INTEGRA BIOSCIENCES AG